
Enhancing clipping solutions for durable, long-term patient outcomes
Leading experts shared new data reinforcing TriClip™ TEER’s safety and effectiveness. The session emphasized early intervention benefits, featuring a live-in-a-box case of successful mixed TR treatment. In the mitral segment, polling showed a shift toward treating more RESHAPE-like patients, highlighting the need for timely referrals. Strong engagement showed momentum for earlier TEER.
Related Videos

Webinar: Aortic & Mitral Valve Disease

AV VALVES 2023: TR – Big Gaps

A decade of Tendyne: C. Klein and P. Denti

M-TEER: patient selection and current evidence

PremiClose 2024: Pediatric cardiologist view

PCR LV 2021: Navitor™

AV VALVES 2023:Decision Making in HF–Tricuspid

MitraClip™ Patient Story: Scott